We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Blood Test Index Offers Earlier Detection of Liver Scarring

By LabMedica International staff writers
Posted on 27 Feb 2026

Metabolic fatty liver disease is highly prevalent and often silent, yet it can progress to fibrosis, cirrhosis, and liver failure. More...

Current first-line blood test scores frequently return indeterminate results, prompting avoidable referrals and additional follow-up testing. A new study now reports that a fibroblast activation protein-based index may enhance early identification of patients at risk of clinically significant liver damage.

Researchers at the Centenary Institute (Sydney, Australia) have developed a diagnostic tool, the FAP-Index, to improve triage of individuals with metabolic fatty liver disease who are at heightened risk of advanced liver fibrosis. The tool is intended to address uncertainty that often arises when existing first-line risk scores yield indeterminate results. It is positioned for early use in the care pathway to support more targeted investigation.

The FAP‑Index combines a simple blood test measuring fibroblast activation protein (FAP) with routinely collected clinical information to generate a more precise assessment of fibrosis risk. FAP is a biomarker directly involved in the biological processes that drive liver scarring. By incorporating a marker central to fibrogenesis, the approach differs from scoring systems that rely on indirect indicators of liver injury.

In a study published in the Journal of Gastroenterology and Hepatology, the researchers report that adding the FAP‑Index to existing first‑line blood test risk scores reduced indeterminate results by up to 70% compared with current screening tools alone. The investigators state that further studies will support the transition of the FAP-Index into routine clinical practice, with the goal of improving outcomes for the growing number of individuals living with metabolic fatty liver disease.

“Fatty liver disease is incredibly common but it’s very difficult to know who has severe liver damage. The FAP‑Index is designed to be simple, affordable and practical, so it can be used early in primary care to identify patients who genuinely need further investigation,” said Ziqi Vincent Wang, PhD student at the Centenary Institute and the University of Sydney.

“With effective therapies becoming available, there is an urgent need for better tools to test patients and more accurately detect advanced fibrosis earlier. By focusing on a protein central to liver scarring and reducing uncertain results, the FAP‑Index has the potential to ease pressure on specialist services while ensuring patients in need receive timely care,” said Professor Mark Gorrell, Laboratory Head in the Centenary Institute’s Centre for Cancer Innovations.

Related Links
Centenary Institute


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.